Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43977   clinical trials with a EudraCT protocol, of which   7312   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-001882-34
    Sponsor's Protocol Code Number:C-935788-058
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-07-30
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-001882-34
    A.3Full title of the trial
    A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    Studio di estensione di Fase 3 in aperto nel Trattamento dell’Anemia Emolitica Autoimmune da Anticorpi Caldi con Fostamatinib Disodico
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    This is a Phase 3 multi-center, open-label extension study to evaluate the long-term safety and efficacy of fostamatinib (R788) in subjects with wAIHA who have completed 24 weeks of participation in study C-935788-057.
    Questo è uno studio di estensione multicentrico di fase 3 in aperto per valutare la sicurezza e l'efficacia a lungo termine di fostamatinib (R788) in soggetti con wAIHA che hanno completato 24 settimane di partecipazione allo studio C-935788-057
    A.3.2Name or abbreviated title of the trial where available
    C-935788-058
    C-935788-058
    A.4.1Sponsor's protocol code numberC-935788-058
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorRIGEL PHARMACEUTICALS, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportRigel Pharmaceuticals, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation Rigel Pharmaceuticals, Inc.
    B.5.2Functional name of contact pointSandra Tong
    B.5.3 Address:
    B.5.3.1Street Address1180 Veterans Boulevard
    B.5.3.2Town/ citySouth San Francisco
    B.5.3.3Post codeCA 94080
    B.5.3.4CountryUnited States
    B.5.4Telephone number+16506241207
    B.5.5Fax number+16503996357
    B.5.6E-mailstong@rigel.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFostamatinib Disodium
    D.3.2Product code [R935788]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFostamatinib
    D.3.9.1CAS number 914295-16-2
    D.3.9.2Current sponsor codeFostamatinib Disodium R935788
    D.3.9.3Other descriptive nameR788, fostamatinib disodium hexahydrate (in USPI/FPI)
    D.3.9.4EV Substance CodeSUB32625
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFostamatinib Disodium
    D.3.2Product code [R935788]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFostamatinib
    D.3.9.1CAS number 914295-16-2
    D.3.9.2Current sponsor codeFostamatinib Disodium R935788
    D.3.9.3Other descriptive nameR788, fostamatinib disodium hexahydrate (in USPI/FPI)
    D.3.9.4EV Substance CodeSUB32625
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Warm antibody autoimmune hemolytic anemia (wAIHA)
    Anemia Emolitica Autoimmune da Anticorpi Caldi (wAIHA)
    E.1.1.1Medical condition in easily understood language
    Autoimmune hemolytic anemia (AIHA) is an acquired disorder manifested by autoantibody- mediated red blood cell (RBC) destruction.
    Anemia Emolitica Autoimmune (AIHA) è un disturbo acquisito che si manifesta con distruzione dei globuli rossi (RBC) autoanticorpati.
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10003825
    E.1.2Term Autoimmune hemolytic anemia
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is:
    • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA)
    L'obiettivo principale di questo studio è:
    • Valutare la sicurezza a lungo termine di fostamatinib nei soggetti con anemia emolitica autoimmune anticorpale calda (wAIHA)
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are:
    • To estimate the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA)
    • To estimate the durability of response in subjects receiving fostamatinib for wAIHA • To assess steroid use in subjects with warm antibody autoimmune hemolytic anemia (wAIHA) treated with fostamatinib..
    Gli obiettivi secondari di questo studio sono:
    • Stimare l'efficacia di fostamatinib in soggetti con anemia emolitica autoimmune anticorpale calda (wAIHA)
    • Stimare la durabilità della risposta nei soggetti che assumono fostamatinib per wAIHA
    • Valutare l'uso di steroidi in soggetti con anemia emolitica autoimmune anticorpale calda (wAIHA) trattati con fostamatinib.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures.
    2. Subject must have completed all 24 weeks of participation in the study C-935788-057.
    3. Female subjects must be either post-menopausal for at least 1 year or surgically sterile; or, if of childbearing potential, must not be pregnant or lactating and must agree to use a highly effective method of birth control throughout the duration of the trial and for 14 days following the last dose. Acceptable methods of birth control are defined as: hormonal contraception (pill, injection or implant) used consistently for at least 30 days prior to baseline an intrauterine device (IUD), or intrauterine hormone-releasing system (IUS), or true abstinence (i.e. abstinence is in line with the preferred and usual lifestyle of the subject).
    4. In the investigator’s opinion, the subject has the ability to understand the nature of the study and any hazards of participation and to communicate satisfactorily with the investigator.
    1. Il soggetto deve essere disposto e in grado di fornire il consenso informato scritto firmando un Modulo di consenso informato approvato dall'IRB prima di sottoporsi a qualsiasi procedura specifica dello studio.
    2. Il soggetto deve aver completato tutte le 24 settimane di partecipazione allo studio C-935788-057.
    3. I soggetti di sesso femminile devono essere in stato di post-menopausa da almeno 1 anno o chirurgicamente sterili; oppure, se potenzialmente fertili, non devono essere in gravidanza o in allattamento e devono accettare di usare un metodo contraccettivo altamente efficace per tutta la durata della sperimentazione e per i 14 giorni successivi all'ultima dose. I metodi contraccettivi accettabili sono definiti come: contraccettivo ormonale (pillola, iniezione o impianto) usato in modo costante da almeno 30 giorni prima della baseline, dispositivo intrauterino (IUD) o sistema intrauterino a rilascio di ormoni (IUS) oppure astinenza completa (ovvero l’astinenza è in linea con lo stile di vita consueto e preferibile del soggetto).
    4. Secondo il parere dello sperimentatore, il soggetto ha la capacità di comprendere la natura dello studio e tutti i rischi della partecipazione e di comunicare in modo soddisfacente con lo sperimentatore.
    E.4Principal exclusion criteria
    1. Any subject who discontinued participation in Study C-935788-057 prior to Week 24.
    1. Qualsiasi soggetto che abbia interrotto la partecipazione allo Studio C-935788-057 prima della Settimana 24.
    E.5 End points
    E.5.1Primary end point(s)
    Safety Endpoints:
    • Adverse events
    • Changes from baseline in selected laboratory values per CTCAE criteria V 5.0
    • Changes from baseline in blood pressure over time

    Efficacy Endpoints:
    • Durable hemoglobin response (Yes/No) within 24 weeks of treatment
    A hemoglobin response is defined as a hemoglobin level of >10 g/dL and =2 g/dL higher than the baseline (i.e, hemoglobin value prior to fostamatinib exposure), during the previous 4 weeks, the steroid dose is not higher than the baseline level, and rescue medication is not administered. A durable response is defined as a hemoglobin response on at least 3 scheduled visits during the first 24 weeks of this study.
    • Hemoglobin response at 48 weeks (Yes/No) defined as subjects who achieve a durable response, as above, and have a hemoglobin response at 48 weeks
    • Hemoglobin response by week 24
    • Partial hemoglobin response, defined as a Hgb change from baseline of =2 g/dL
    • Subjects who achieve steroid dose < 10 mg/day (prednisone equivalent)
    • Change from baseline in hemoglobin values over time
    • Change from baseline in steroid dose
    • Subjects requiring any rescue during this study
    • Overall duration of response and duration of first response
    • Subjects who decrease any concomitant wAIHA therapy
    Endpoint di sicurezza:
    • Eventi avversi
    • Variazioni rispetto alla baseline in valori di laboratorio selezionati secondo i criteri CTCAE V 5.0
    • Variazioni rispetto alla baseline della pressione sanguigna nel tempo
    Endpoint di efficacia:
    • Risposta duratura dell'emoglobina (Si/No) entro 24 settimane dal trattamento
    Una risposta dell'emoglobina è definita come un livello di emoglobina di >10 g/dL e = 2 g/dL più elevato rispetto alla baseline (ossia il valore dell’emoglobina prima dell’esposizione a fostamatinib), durante le 4 settimane precedenti, la dose di steroidi non è superiore rispetto al livello basale e non sono stati somministrati farmaci di salvataggio.
    Una risposta duratura è definita come una risposta dell'emoglobina in almeno 3 visite programmate durante le prime 24 settimane di questo studio.
    • Risposta dell'emoglobina a 48 settimane (Sì/No) definita come soggetti che ottengono una risposta duratura, come sopra, e hanno una risposta dell’emoglobina a 48 settimane
    • Risposta dell'emoglobina entro la settimana 24
    • Risposta parziale dell'emoglobina, definita come una variazione dell’Hgb rispetto alla baseline di =2 g/dL
    • Soggetti che raggiungono una dose di steroidi < 10 mg/die (equivalente del prednisone)
    • Variazione rispetto alla baseline dei valori di emoglobina nel tempo
    • Variazione rispetto alla baseline della dose di steroidi
    • Soggetti che necessitano di eventuale salvataggio durante questo studio
    • Durata complessiva della risposta e durata della prima risposta
    • Soggetti che riducono qualsiasi terapia concomitante per la wAIHA
    E.5.1.1Timepoint(s) of evaluation of this end point
    24 week evaluation
    24 settimane
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    in Aperto
    Open Label
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA46
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belarus
    Canada
    Georgia
    Russian Federation
    Ukraine
    United States
    Austria
    Belgium
    Bulgaria
    Denmark
    France
    Germany
    Hungary
    Italy
    Netherlands
    Norway
    Romania
    Spain
    United Kingdom
    Czechia
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 81
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state14
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 40
    F.4.2.2In the whole clinical trial 81
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Extended treatment will be available to eligible subjects under a separate a protocol. All other subjects will return to standard treatment.
    Il trattamento esteso sarà disponibile per soggetti idonei in base a un protocollo separato. Tutti gli altri soggetti torneranno al trattamento standard.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-04-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-05-19
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2022-11-05
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 27 03:40:30 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA